Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | SQLE | Q14534 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | FNTA | P49354 | 2/20 | 0.55 |
| ▸ | FNTB | P49356 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362041 | 1.00 | KMT2A (0.70) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL122098 | 0.91 | — | — | |
| SCHEMBL9576827 | 0.90 | KMT2A (0.61) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL2515732 | 0.85 | KMT2A (0.94) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL2515736 | 0.85 | KMT2A (0.94) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL23802597 | 0.83 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL8819997 | 0.83 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL39067 | 0.83 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL21639794 | 0.83 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL21823197 | 0.83 | KMT2A (1.00) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038573-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | CLIFF-CARTWRIGHT CORPORATION | 2019-02-07 | — | — | US | claimed |
| EP-3295794-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND RELIEVING MUSCLE CRAMPS AND FOR RECOVERY FROM NEUROMUSCULAR IRRITABILITY AND FATIGUE FOLLOWING EXERCISE | Flex Pharma, Inc. (US) | 2018-03-21 | — | — | EP | claimed |
| US-20170333483-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION | 2017-11-23 | — | — | US | claimed |
| EP-2629610-B1 | METHODS AND COMPOSITIONS FOR PREVENTING AND RELIEVING MUSCLE CRAMPS AND FOR RECOVERY FROM NEUROMUSCULAR IRRITABILITY AND FATIGUE FOLLOWING EXERCISE | FLEX PHARMA INC (US) | 2017-09-06 | — | — | EP | claimed |
| US-9737567-B2 | Methods for enhancing hematopoietic stem/progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-08-22 | — | — | US | claimed |
| EP-3131541-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | Flex Pharma, Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| US-20170042834-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | CLIFF-CARTWRIGHT CORPORATION | 2017-02-16 | — | — | US | claimed |
| CN-106232110-A | Ion channel activation agent and using method | 弗莱克斯制药股份有限公司 | 2016-12-14 | — | — | CN | claimed |
| WO-2015160843-A1 | ION CHANNEL ACTIVATORS AND METHODS OF USE | FLEX PHARMA, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| US-20150272996-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION | 2015-10-01 | — | — | US | claimed |
| US-9051548-B2 | Methods for enhancing hematopoietic stem/progenitor cell engraftment | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-06-09 | — | — | US | claimed |
| EP-2629610-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND RELIEVING MUSCLE CRAMPS AND FOR RECOVERY FROM NEUROMUSCULAR IRRITABILITY AND FATIGUE FOLLOWING EXERCISE | Bean, Bruce P. (US) | 2013-08-28 | — | — | EP | claimed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | claimed |
| WO-2012012498-A9 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| WO-2012015882-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND RELIEVING MUSCLE CRAMPS AND FOR RECOVERY FROM NEUROMUSCULAR IRRITABILITY AND FATIGUE FOLLOWING EXERCISE | BEAN BRUCE P (US) | 2012-02-02 | — | — | WO | claimed |
| US-20120027693-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND RELIEVING MUSCLE CRAMPS AND FOR RECOVERY FROM NEUROMUSCULAR IRRITABILITY AND FATIGUE FOLLOWING EXERCISE | CLIFF-CARTWRIGHT CORPORATION | 2012-02-02 | — | — | US | claimed |
| WO-2012012498-A2 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-01-26 | — | — | WO | claimed |
| WO-2010091052-A2 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-08-12 | — | — | WO | claimed |
| US-6372793-B1 | NERVOUS SYSTEM DISORDERS, METHYLATION DEMETHYLATION FOR NEUROMODULATOR FUNCTIONS | FLORIDA AGRICULTURAL & MECHANICAL UNIVERSITY | 2002-04-16 | — | — | US | claimed |
| US-5202456-A | Anticarcinogenic agents; methylating transferase inhibitors; farnesyl or geranyl sulfur-, oxygen or selenium-containing derivatives | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1993-04-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | TRPV1, TRPC4, TRPC3 | KMT2A 4160/4885MAPT 3407/4885MEN1 2763/4885 |
| US-20120027693-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND RELIEVING MUSCLE CRAMPS AND FOR RECOVERY FROM NEUROMUSCULAR IRRITABILITY AND FATIGUE FOLLOWING EXERCISE | TRPA1, TRPV1, TRPV5 | KMT2A 3814/4885MAPT 3485/4885MEN1 2701/4885 |
| US-20150272996-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | HCLS1, HGF, MCL1 | KMT2A 1244/4885MAPT 4785/4885MEN1 3334/4885 |
| US-20170333483-A1 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT | HCLS1, HGF, MCL1 | KMT2A 1244/4885MAPT 4785/4885MEN1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.